DaVita

DaVita Equity

The The Equity of DaVita (DVA) as of Nov 5, 2026 is 1.16 B USD. In the previous year, The Equity was 2.09 B USD — a change of -44.61% (lower).

Equity

1.16 BUSD

YoY

-44.61%

Last updated:

In 2025, DaVita's equity was 1.16 B USD, a -44.61% increase from the 2.09 B USD equity in the previous year.

The DaVita Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
5.03 B USD
Jan 1, 2019
3.50 B USD
Jan 1, 2020
2.90 B USD
Jan 1, 2021
2.37 B USD
Jan 1, 2022
2.22 B USD
Jan 1, 2023
2.74 B USD
Jan 1, 2024
2.09 B USD
Jan 1, 2025
1.16 B USD
The DaVita Equity history
YEAREquityYoY
1.16 BUSD-44.61%
2.09 BUSD-23.77%
2.74 BUSD+23.31%
2.22 BUSD-6.17%
2.37 BUSD-18.15%
2.90 BUSD-17.23%
3.50 BUSD-30.47%
5.03 BUSD-14.66%
5.90 BUSD+1.28%
5.82 BUSD-2.11%
5.95 BUSD-3.91%
6.19 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DaVita Stock analysis

What does DaVita do? DaVita Inc. is a company headquartered in Denver, Colorado, specializing in the provision and management of outpatient dialysis treatments (renal replacement therapy) and related services. The company was founded in 1999 and has since experienced impressive growth, with a presence in over ten countries worldwide. The history of DaVita traces back to the origin of its business model: outpatient dialysis treatment. This is a form of renal replacement therapy where patients can be treated outside of the hospital, in a dedicated center or even in their own homes. This type of dialysis is less intimidating compared to inpatient treatment in a hospital and can be much more flexible in terms of scheduling. DaVita took this idea and brought it to the market in the US and other countries, where it has proven to be extremely successful. Nowadays, DaVita operates in three main business segments. The first is the patient care segment, which focuses on providing dialysis treatments and related services. Here, DaVita offers outpatient dialysis centers where patients can receive regular treatment. Another important aspect of this segment is patient and family education, integrating them into the treatment process and helping them lead as normal a life as possible. The second core area is the pharmaceutical supply business. DaVita has an extensive network of facilities and suppliers, as well as its own pharmacies where the necessary medications for dialysis patients are manufactured and stored. DaVita also handles billing with insurance and other payment entities to ensure seamless patient care. The third core area of DaVita is the international supply company. Here, DaVita offers its services in over ten countries worldwide, including Mexico, Colombia, Brazil, Saudi Arabia, and Canada. DaVita has steadily expanded its international business in recent years and aims to have a presence in even more countries in the future. But DaVita does not limit itself to these three core areas. The company is also known for its innovative research and development efforts aimed at improving the treatment of kidney disease and developing new technologies. Products offered by DaVita include innovative dialysis devices, advanced care management software, and intelligent sensors for automated patient monitoring. In its over 20-year history, DaVita has overcome many challenges, including regulatory issues, economic fluctuations, and ever-growing competition. Despite these challenges, the company has steadily expanded its position in the industry and established itself as a leading provider of dialysis and related services. DaVita's success is based on a culture of results orientation and a strong commitment to improving patient outcomes. The company understands that each patient has unique needs and that the treatment of kidney disease requires a lifelong commitment. Therefore, DaVita emphasizes individual care and collaboration with patients and their families to ensure optimal care. Overall, DaVita is an innovative company specializing in the provision of dialysis treatments and related services. The company has overcome many challenges in its history and established itself as a leading provider of dialysis and related services. DaVita is committed to improving the quality of life for dialysis patients worldwide and continuously optimizing the treatment of kidney disease. DaVita is one of the most popular companies on Eulerpool.

Equity Details

Analyzing DaVita's Equity

DaVita's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding DaVita's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating DaVita's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

DaVita's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in DaVita’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about DaVita stock

The Equity of DaVita is 1.16 B USD in 2025.

The Equity of DaVita changed from 2.09 B USD to 1.16 B USD, representing a -44.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity DaVita since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's DaVita historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — DaVita

All Key Metrics — DaVita